Código QR (código de barras bidimensional)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

BackgroundCombining an antiangiogenic agent with an anti-PD-1 agent is a promising strategy for unresectable hepatocellular carcinoma (HCC).AimsTo explore the effectiveness and tolerability of lenvatinib plus camrelizumab vs. lenvatinib monotherapy as a first-line treatment for unresectable HCC.Meth...

ver descrição completa

Na minha lista:
Principais autores: Qi Li, Mengran Cao, Guosheng Yuan, Xiao Cheng, Mengya Zang, Ming Chen, Xiaoyun Hu, Jing Huang, Rong Li, Yabing Guo, Jian Ruan, Jinzhang Chen
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2022-02-01
coleção:Frontiers in Oncology
Assuntos:
hepatocellular carcinoma
unresectable
lenvatinib
camrelizumab
objective response
survival
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2022.809709/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados